Fig. 5
Predominant growth suppression on established subcutaneous MIA PaCa-2 xenografts by PAR1-targeted chimeric antigen receptor (CAR)-T cells in vivo. A Schematic representation of the detailed treatment schedule in the in vivo study. B, C Endpoint dissection of treated mice. B Photograph of a representative tumor mass. After dissection at week 10, tumor xenografts were first measured (the largest size was 2.9 cm) and then fixed with formalin. C For each treated mouse group, individual dissected tumor volumes (cm3) and individual dissected tumor weights (g) are expressed as scatterplots (n = 6 per group; *** p < 0.001). D Growth curve of mean body weight (g) of each treated mouse group showed no significant difference over time, whereas E growth curves of individual MIA PaCa-2 xenografts treated with 1 × PBS or indicated T cells. At the endpoint (at week 10), residual tumors treated with PAR1CAR-T cells were significantly smaller than those in control groups (n = 6 per group; *** p < 0.001). Two independent experiments are shown with similar results, and mice that died during the experimental period are shown in red